Financials in USD. Standardized financial statements.
A compact view of how The Oncology Institute, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue? | $502.73M | $393.41M | $324.24M | $252.48M | $203.00M | $187.51M | $155.41M | $113.16M |
| Revenue Growth? | +27.8% | +21.3% | +28.4% | +24.4% | +8.3% | +20.7% | +37.3% | 0.0% |
| Cost of Revenue? | $426.29M | $339.42M | $264.67M | $200.39M | $162.16M | $150.64M | $125.46M | $86.88M |
| Gross Profit? | $76.44M | $54.00M | $59.57M | $52.09M | $40.85M | $36.88M | $29.94M | $26.28M |
| Gross Margin? | +15.2% | +13.7% | +18.4% | +20.6% | +20.1% | +19.7% | +19.3% | +23.2% |
| Operating Expenses? | $112.52M | $114.11M | $136.59M | $134.04M | $86.71M | $45.07M | $32.59M | $21.49M |
| Operating Income? | -$36.08M | -$60.12M | -$77.02M | -$81.95M | -$45.86M | -$8.20M | -$2.64M | $4.79M |
| EBITDA? | -$42.52M | -$53.83M | -$54.28M | -$67.60M | -$42.04M | -$11.29M | $307,109 | $9.08M |
| Income Before Tax | -$60.74M | -$64.66M | -$83.10M | -$91,000 | -$11.60M | -$14.81M | -$2.64M | $4.86M |
| Income Tax Expense | -$131,000 | $0 | -$36,000 | -$243,000 | -$671,000 | -$492,823 | $1.38M | $912,745 |
| Net Income? | -$60.61M | -$64.66M | -$83.07M | $152,000 | -$10.93M | -$14.32M | -$4.02M | $3.95M |
| EPS? | $-0.54 | $-0.71 | $-0.92 | $0.00 | $-0.16 | $-0.24 | $-0.06 | $0.14 |
| Diluted EPS? | $-0.54 | $-0.71 | $-0.92 | $-0.21 | $-0.16 | $-0.24 | $-0.06 | $0.14 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality